

Contents

Preface XV

List of Contributors XVII

Introduction 1

Anne Skaja Robinson and Patrick J. Loll

Expression 2

Solubilization and Structural Methods 5

Abbreviations 7

References 7

Part One Expression Systems 11

1 Bacterial Systems 13

James Samuelson

1.1 Introduction 13

1.2 Understanding the Problem 14

1.3 Vector/Promoter Types 15

1.4 T7 Expression System 20

1.5 Tunable T7 Expression Systems 21

1.6 Other Useful Membrane Protein Expression Strains 22

1.7 Clone Stability 23

1.8 Media Types 24

1.9 Fusion Partners/Membrane Targeting Peptides 25

1.10 Chaperone Overexpression 26

1.11 Cautionary Notes Related to Chaperone Overexpression 27

1.12 Emerging Role of Quality Control Proteases 27

1.13 Tag Selection 28

1.14 Potential Expression Yield 29

1.15 Strategies to Overcome Protein Instability 30

Acknowledgments 31

Abbreviations 31

References 31

| | | |
|----------|--|-----------|
| 2 | Membrane Protein Expression in <i>Saccharomyces cerevisiae</i> | 37 |
| | <i>Zachary Britton, Carissa Young, Özge Can, Patrick McNeely, Andrea Naranjo, and Anne Skaja Robinson</i> | |
| 2.1 | Introduction | 37 |
| 2.2 | Getting Started | 38 |
| 2.2.1 | Promoter Systems | 38 |
| 2.2.1.1 | Constitutive Promoters | 38 |
| 2.2.1.2 | Inducible Promoters | 38 |
| 2.2.2 | Host Strains, Selection Strategies, and Plasmids | 39 |
| 2.2.2.1 | Host Strains | 39 |
| 2.2.2.2 | Selection Strategies | 40 |
| 2.2.2.3 | Plasmids and Homologous Recombination | 40 |
| 2.2.3 | Expression Conditions | 42 |
| 2.3 | Special Considerations | 43 |
| 2.3.1 | Post-Translational Modifications | 43 |
| 2.3.1.1 | Glycosylation | 43 |
| 2.3.1.2 | Disulfide Bond Formation | 44 |
| 2.3.2 | Lipid Requirements | 44 |
| 2.3.2.1 | Glycerophospholipids | 45 |
| 2.3.2.2 | Sphingolipids | 46 |
| 2.3.2.3 | Sterols | 46 |
| 2.3.3 | Signal Sequences | 47 |
| 2.3.4 | Topology | 47 |
| 2.3.5 | Cellular Responses to Membrane Protein Expression | 49 |
| 2.3.5.1 | UPR | 49 |
| 2.3.5.2 | HSR | 49 |
| 2.4 | Case Studies | 49 |
| 2.4.1 | Ste2p | 50 |
| 2.4.2 | Pma1p | 50 |
| 2.4.3 | CFTR | 60 |
| 2.5 | Conclusions | 61 |
| | Abbreviations | 62 |
| | References | 62 |
| 3 | Expression Systems: <i>Pichia pastoris</i> | 75 |
| | <i>Fatima Alkhalfiou, Christel Logez, Olivier Bornert, and Renaud Wagner</i> | |
| 3.1 | Introduction | 75 |
| 3.2 | A (Brief) Summary on the (Long) History of <i>P. pastoris</i> | 75 |
| 3.3 | Introducing <i>P. pastoris</i> as a Biotechnological Tool: Its (Extended) Strengths and (Limited) Weaknesses | 76 |
| 3.4 | Basics of the <i>P. pastoris</i> Expression System | 77 |
| 3.4.1 | Methanol Utilization Pathway | 77 |
| 3.4.2 | Host Strains and Plasmids | 78 |
| 3.4.3 | Transformation and Clone Selection Strategies | 80 |

| | | |
|----------|--|------------|
| 3.4.4 | Expression Conditions and Culturing Formats | 80 |
| 3.5 | Successful Large-Scale Expression of Membrane Proteins Using <i>P. pastoris</i> | 81 |
| 3.5.1 | <i>P. pastoris</i> for Membrane Protein Expression | 81 |
| 3.5.2 | Common Trends for an Efficient Expression of Membrane Proteins in <i>P. pastoris</i> | 92 |
| 3.6 | Guidelines for Optimizing Membrane Protein Expression in <i>P. pastoris</i> Using GPCRs as Models | 94 |
| 3.6.1 | Design and Selection of Enhanced Expression Clones | 95 |
| 3.6.2 | Optimization of the Expression Conditions | 96 |
| 3.6.3 | Yeast Cell Lysis | 98 |
| 3.7 | Conclusions and Future Directions | 99 |
| | Acknowledgments | 99 |
| | Abbreviations | 99 |
| | References | 100 |
| 4 | Heterologous Production of Active Mammalian G-Protein-Coupled Receptors Using Baculovirus-Infected Insect Cells | 109 |
| | <i>Mark Chiu, Brian Estvander, Timothy Esbenshade, Steve Kakavas, Kathy Krueger, Marc Lake, and Ana Pereda-Lopez</i> | |
| 4.1 | Introduction | 109 |
| 4.2 | Experimental | 113 |
| 4.2.1 | Generation of Recombinant Baculovirus | 113 |
| 4.2.2 | Baculovirus Infection of Insect Cells | 115 |
| 4.2.3 | Case Study: Histamine H ₃ Receptor | 118 |
| 4.2.3.1 | Solubilization of the Histamine H ₃ Receptor | 125 |
| 4.2.3.2 | Assay Validation | 125 |
| 4.2.3.3 | Competition Analysis of Solubilized versus Membrane-Bound Receptor | 126 |
| 4.3 | Conclusions and Future Perspectives | 128 |
| 4.3.1 | Executive Summary | 130 |
| 4.3.2 | Future Perspectives | 130 |
| | Abbreviation | 131 |
| | References | 131 |
| 5 | Membrane Protein Expression in Mammalian Cells | 139 |
| | <i>Deniz B. Hizal, Erika Ohsfeldt, Sunny Mai, and Michael J. Betenbaugh</i> | |
| 5.1 | Introduction | 139 |
| 5.2 | Mammalian Systems | 140 |
| 5.2.1 | Cell Culture Types and Media Optimization | 140 |
| 5.2.1.1 | Adherent Cell Culture | 140 |
| 5.2.1.2 | Suspension Cell Culture | 141 |
| 5.2.1.3 | Batch and Fed-Batch Culture | 141 |
| 5.2.1.4 | Perfusion Process | 141 |
| 5.2.1.5 | Media Optimization | 141 |

| | | |
|---------|---|-----|
| 5.2.2 | Gene Delivery and Expression in Mammalian Systems | 143 |
| 5.2.2.1 | High Transfection Efficiency in Adherent Cell Cultures with Cationic Liposome | 143 |
| 5.2.3 | Post-Translational Modifications in Mammalian Systems | 147 |
| 5.2.3.1 | Glycosylation | 148 |
| 5.2.3.2 | Protein Lipidation | 149 |
| 5.3 | Case Studies | 150 |
| 5.3.1 | Increasing Membrane Protein Expression by Virus Vectors | 150 |
| 5.3.2 | Anti-apoptosis Engineering for Increasing Membrane Protein Expression | 152 |
| 5.3.3 | Increasing Membrane Protein Expression by Chaperones | 156 |
| 5.3.4 | Membrane Protein Expression in Cancer Cell Lines | 157 |
| 5.3.5 | Membrane Proteins as Biotherapeutics | 158 |
| 5.4 | Conclusions | 159 |
| | Abbreviations | 160 |
| | References | 161 |

6 Membrane Protein Production Using Photosynthetic Bacteria: A Practical Guide 167

Philip D. Laible, Donna L. Mielke, and Deborah K. Hanson

| | | |
|---------|--|-----|
| 6.1 | Introduction | 167 |
| 6.1.1 | The Membrane Protein Problem | 167 |
| 6.1.2 | Exploiting the Physiology of Photosynthetic Bacteria | 168 |
| 6.1.3 | Expression Strategies | 170 |
| 6.1.3.1 | Design of the Expression Plasmids | 170 |
| 6.1.3.2 | Design of Expression Hosts | 172 |
| 6.1.3.3 | Autoinduction Conditions | 173 |
| 6.1.4 | Summary of Success Stories | 174 |
| 6.2 | Preparation of Expression Constructs | 175 |
| 6.2.1 | Platform Vector Preparation | 175 |
| 6.2.1.1 | Large-Scale Vector Preparation Protocol for Ligation-Dependent Cloning | 175 |
| 6.2.1.2 | Large-Scale Vector Preparation Protocol for LIC | 176 |
| 6.2.2 | Design of Oligonucleotide Primers for Gene Amplification and Cloning | 177 |
| 6.2.2.1 | Ligation-Dependent Cloning | 177 |
| 6.2.2.2 | LIC | 177 |
| 6.2.3 | Target Gene Preparation | 178 |
| 6.2.3.1 | PCR Amplification of Target Gene | 178 |
| 6.2.3.2 | Restriction Enzyme Digestion of PCR Amplicon | 178 |
| 6.2.3.3 | Digestion of PCR Amplicon to Generate LIC Overhangs | 178 |
| 6.2.4 | Cloning of Digested Amplicons | 178 |
| 6.2.4.1 | Generation of Recombinant Plasmids | 178 |
| 6.2.4.2 | Transformation of <i>E. coli</i> with Ligation or LIC Reactions | 179 |
| 6.2.5 | Screening for Successful Insertion of Target Gene into Platform Vector | 179 |

| | | |
|---------|---|-----|
| 6.3 | Transfer of Plasmid DNA to <i>Rhodobacter</i> via Conjugal Mating | 180 |
| 6.3.1 | Transformation of <i>E. coli</i> S17-1 | 180 |
| 6.3.2 | Conjugation of <i>E. coli</i> with <i>R. sphaeroides</i> | 180 |
| 6.4 | Small-Scale Screening for Expression and Localization of Target Protein in <i>Rhodobacter</i> | 181 |
| 6.4.1 | Small-Scale Growth and Preparation of Samples for SDS-PAGE | 182 |
| 6.4.1.1 | Growth and Harvest of Expression Strains | 182 |
| 6.4.1.2 | Preparing Whole-Cell Samples for SDS-PAGE | 183 |
| 6.4.1.3 | Preparing Membranes and the Soluble Fraction for SDS-PAGE | 184 |
| 6.4.2 | SDS-PAGE Followed by Electroblotting of Proteins to PVDF Membrane | 185 |
| 6.4.3 | Immunoblot Development | 186 |
| 6.5 | Large-Scale Culture | 187 |
| 6.5.1 | Growth and Harvest of Expression Culture | 187 |
| 6.5.2 | Cell Lysis | 188 |
| 6.5.3 | Membrane Isolation | 188 |
| 6.6 | Detergent Solubilization and Chromatographic Purification of Expressed Membrane Proteins | 189 |
| 6.6.1 | Solubilization of Membrane Proteins | 190 |
| 6.6.2 | Chromatography | 190 |
| 6.6.2.1 | Bench-Top Affinity Chromatography | 190 |
| 6.6.2.2 | Affinity Chromatography Using an ÄKTA-FPLC™ | 191 |
| 6.7 | Protein Identification and Assessment of Purity | 192 |
| 6.8 | Preparations of Specialized <i>Rhodobacter</i> Membranes | 192 |
| | Appendix: Media and Buffer Formulations | 194 |
| | Abbreviations | 196 |
| | References | 197 |

Part Two Protein-Specific Considerations 199

| | | |
|---------|---|-----|
| 7 | Peripheral Membrane Protein Production for Structural and Functional Studies | 201 |
| | <i>Brian J. Bahnsen</i> | |
| 7.1 | Introduction | 201 |
| 7.2 | Case Studies of Peripheral Membrane Proteins | 204 |
| 7.2.1 | Electrostatic Interactions | 204 |
| 7.2.1.1 | Case 1: Cytochrome <i>c</i> ₂ | 205 |
| 7.2.1.2 | Case 2: Group IB Secreted Phospholipase A ₂ | 205 |
| 7.2.2 | Hydrophobic Patch | 207 |
| 7.2.2.1 | Case 1: Plasma Platelet-Activating Factor Acetylhydrolase | 208 |
| 7.2.2.2 | Case 2: Human Serum Paraoxonase 1 | 210 |
| 7.2.3 | Covalent Lipid Anchor | 210 |
| 7.2.3.1 | Case 1: Recoverin | 211 |
| 7.2.3.2 | Case 2: Intracellular Platelet-Activating Factor Acetylhydrolase Type II | 212 |
| 7.2.4 | Case 3: Palmitoylation of Human Proteins in Cell Culture | 212 |

| | | |
|----------|--|-----|
| 7.2.5 | Lipid-Binding Domain | 212 |
| 7.2.5.1 | Case 1: Pleckstrin Homology Domain | 213 |
| 7.2.5.2 | Case 2: C2 Domain | 213 |
| 7.3 | Conclusions | 214 |
| | Acknowledgments | 215 |
| | Abbreviations | 215 |
| | References | 215 |
| 8 | Expression of G-Protein-Coupled Receptors | 219 |
| | <i>Alexei Yeliseev and Krishna Vukoti</i> | |
| 8.1 | Introduction | 219 |
| 8.2 | Bacterial Expression of GPCRs | 220 |
| 8.3 | Expression of GPCRs in Inclusion Bodies, and Refolding | 228 |
| 8.4 | Expression of GPCRs in Yeast | 229 |
| 8.5 | Expression of GPCRs in Insect Cells | 231 |
| 8.6 | Expression of GPCRs in Mammalian Cell Lines | 234 |
| 8.7 | Expression of GPCRs in Retina Rod Cells | 234 |
| 8.8 | Expression of GPCRs in a Cell-Free System | 235 |
| 8.9 | Stabilization of GPCRs during Solubilization and Purification | 238 |
| 8.10 | Conclusions | 238 |
| | Acknowledgments | 239 |
| | Abbreviations | 239 |
| | References | 240 |
| 9 | Structural Biology of Membrane Proteins | 249 |
| | <i>David Salom and Krzysztof Palczewski</i> | |
| 9.1 | Introduction | 249 |
| 9.2 | Folding and Structural Analysis of Membrane Proteins | 249 |
| 9.2.1 | Folding | 249 |
| 9.2.2 | Prediction Methods | 251 |
| 9.2.3 | Membrane Insertion | 251 |
| 9.2.4 | Estimating the Molecular Weight of Membrane Proteins | 252 |
| 9.2.5 | Amino Acid Composition | 252 |
| 9.2.6 | Transmembrane Helix Association Motifs and Membrane Protein Oligomerization | 253 |
| 9.2.7 | Post-Translational Modifications | 254 |
| 9.2.7.1 | Glycosylation | 255 |
| 9.2.7.2 | Palmitoylation | 255 |
| 9.2.8 | Sequence Modifications | 256 |
| 9.2.9 | Lipids and Water | 258 |
| 9.2.10 | Purity and Contaminants | 260 |
| 9.2.11 | Current Trends in the Crystallization of α -Helical Membrane Proteins | 260 |
| 9.3 | Test Cases | 261 |
| 9.3.1 | Rhodopsin | 261 |

| | | |
|---------|---|-----|
| 9.3.2 | RPE65 | 264 |
| 9.3.2.1 | Expression in <i>E. coli</i> | 264 |
| 9.3.2.2 | Expression in <i>Sf9</i> Cells | 264 |
| 9.3.2.3 | Purification from Native Sources | 264 |
| 9.3.3 | Transmembrane Domain of M2 Protein from Influenza A Virus | 265 |
| | Acknowledgments | 267 |
| | Abbreviations | 267 |
| | References | 267 |

Part Three Emerging Methods and Approaches 275

| | | |
|-----------|---|------------|
| 10 | Engineering Integral Membrane Proteins for Expression and Stability | 277 |
| | <i>Igor Dodevski and Andreas Plückthun</i> | |
| 10.1 | Introduction | 277 |
| 10.2 | Engineering Higher Expression | 278 |
| 10.2.1 | Directed Evolution of a GPCR for Higher Expression | 280 |
| 10.2.2 | Increasing Expression by Random Mutagenesis and Dot-Blot Based Screening | 286 |
| 10.3 | Engineering Higher Stability | 288 |
| 10.3.1 | Stabilizing a Prokaryotic IMP by Cysteine-Scanning, Random Mutagenesis, and Screening in a 96-Well Assay Format | 289 |
| 10.3.2 | Stabilizing GPCRs by Alanine-Scanning and Single-Clone Screening | 290 |
| 10.3.3 | Stabilizing GPCRs by Random Mutagenesis and Screening in a 96-Well Assay Format | 291 |
| 10.4 | Conclusions | 294 |
| | Abbreviations | 295 |
| | References | 295 |
| 11 | Expression and Purification of G-Protein-Coupled Receptors for Nuclear Magnetic Resonance Structural Studies | 297 |
| | <i>Fabio Casagrande, Klaus Maier, Hans Kiefer, Stanley J. Opella, and Sang Ho Park</i> | |
| 11.1 | Introduction: G-Protein-Coupled Receptor Superfamily | 297 |
| 11.2 | CXCR1 | 298 |
| 11.3 | GPCR Structures | 299 |
| 11.4 | NMR Studies of GPCRs | 300 |
| 11.5 | Expression Systems | 301 |
| 11.6 | Cloning of CXCR1 into pGEX2a | 303 |
| 11.7 | Expression of CXCR1 | 304 |
| 11.8 | Purification | 305 |
| 11.9 | Refolding and Reconstitution | 306 |
| 11.10 | Binding and Activity Measurements | 307 |

| | | |
|-----------|---|------------|
| 11.10.1 | NMR Samples | 308 |
| 11.11 | NMR Spectra | 309 |
| | Acknowledgments | 310 |
| | Abbreviations | 311 |
| | References | 311 |
| 12 | Solubilization, Purification, and Characterization of Integral Membrane Proteins | 317 |
| | <i>Víctor Lórenz-Fonfría, Alex Perálvarez-Marín, Esteve Padrós, and Tsvetana Lazarova</i> | |
| 12.1 | Introduction | 317 |
| 12.2 | Solubilization of IMPs | 319 |
| 12.2.1 | Physicochemical Characteristics of Detergents | 319 |
| 12.2.2 | Classification of Detergents | 321 |
| 12.2.2.1 | Nonionic Detergents | 321 |
| 12.2.2.2 | Ionic Detergents | 321 |
| 12.2.2.3 | Zwitterionic Detergents | 322 |
| 12.2.2.4 | Recently Developed Detergents | 322 |
| 12.2.3 | New Solubilizing Agents | 322 |
| 12.2.4 | Solubilization Process | 322 |
| 12.2.5 | The Means of a Successful Solubilization of IMPs | 324 |
| 12.2.6 | “All” or “Not All” Lipids and If “Purer Is Better” | 325 |
| 12.2.7 | Stability of the Protein–Detergent Solutions | 325 |
| 12.3 | IMP Purification | 326 |
| 12.3.1 | Strategy Definition | 326 |
| 12.3.1.1 | HTP Methods | 327 |
| 12.3.2 | Purification Process | 328 |
| 12.3.2.1 | Hydrophobicity | 328 |
| 12.3.2.2 | Charge | 328 |
| 12.3.2.3 | Size | 329 |
| 12.3.2.4 | Affinity | 330 |
| 12.3.3 | New Approaches and Advances in Purification | 333 |
| 12.3.3.1 | Magnetic Beads | 333 |
| 12.3.3.2 | Phase Separation Methods | 334 |
| 12.4 | Characterization of Solubilized IMPs | 334 |
| 12.4.1 | Sample Homogeneity and Protein Oligomeric State | 334 |
| 12.4.1.1 | SEC | 334 |
| 12.4.1.2 | Static Light Scattering (SLS) | 335 |
| 12.4.1.3 | Analytical Ultracentrifugation (AUC) | 335 |
| 12.4.1.4 | Blue-Native Electrophoresis (BN-PAGE) | 336 |
| 12.4.2 | Structural Characterization | 336 |
| 12.4.2.1 | Circular Dichroism (CD) | 336 |
| 12.4.2.2 | IR Spectroscopy | 337 |
| 12.4.2.3 | NMR Spectroscopy | 337 |
| 12.4.3 | Measurement and Characterization of Ligand Binding | 339 |

| | | |
|----------|--|-----|
| 12.4.3.1 | Isothermal Titration Calorimetry (ITC) | 339 |
| 12.4.3.2 | Spectroscopic Methods | 340 |
| | Appendix | 341 |
| | Acknowledgments | 348 |
| | Abbreviations | 348 |
| | References | 349 |

13 Stabilizing Membrane Proteins in Detergent and Lipid Systems 361

Mark Lorch and Rebecca Batchelor

| | | |
|----------|--|-----|
| 13.1 | Introduction | 361 |
| 13.2 | Choice of Detergent: Solubilization versus Stability | 361 |
| 13.2.1 | Detergents: General Characteristics | 362 |
| 13.2.1.1 | Ionic Detergents | 363 |
| 13.2.1.2 | Zwitterionic Detergents | 363 |
| 13.2.1.3 | Nonionic Detergents | 364 |
| 13.2.1.4 | Detergent-Like Phospholipids | 364 |
| 13.2.2 | Solubilization | 365 |
| 13.3 | Mitigating Protein Denaturation | 366 |
| 13.3.1 | Mixed Detergent Systems | 366 |
| 13.3.1.1 | Micelles | 366 |
| 13.3.1.2 | Bicelles | 368 |
| 13.3.2 | Detergent-Free Bilayer Systems | 370 |
| 13.3.2.1 | Lipid Nanodisk | 370 |
| 13.3.2.2 | Liposomes | 372 |
| 13.3.3 | Detergent-Mediated Reconstitution of Proteoliposomes | 372 |
| 13.3.3.1 | Dilution Method | 373 |
| 13.3.3.2 | Dialysis versus Hydrophobic Absorption | 374 |
| 13.3.3.3 | Detergent Saturation | 375 |
| 13.3.4 | Lipid Composition | 375 |
| 13.3.4.1 | Hydrophobic Mismatch | 376 |
| 13.3.4.2 | Curvature Elastic Stress | 378 |
| 13.3.4.3 | Specific Lipid Effects | 380 |
| 13.4 | Making or Selecting a Stable Protein | 381 |
| 13.5 | Conclusions | 382 |
| | Abbreviations | 382 |
| | References | 383 |

14 Rapid Optimization of Membrane Protein Production Using Green Fluorescent Protein-Fusions and Lemo21(DE3) 391

Susan Schlegel, Mirjam Klepsch, Dimitra Gialama, David Wickström, David Drew, and Jan-Willem de Gier

| | | |
|------|---------------|-----|
| 14.1 | Introduction | 391 |
| 14.2 | Main Protocol | 392 |

| | | |
|--------|---|-----|
| 14.2.1 | Determination of Membrane Protein Topology and Selection of Expression Vector | 392 |
| 14.2.2 | Identification of the Optimal Expression Conditions in Lemo21(DE3) Using Whole-Cell and In-Gel Fluorescence | 394 |
| 14.2.3 | Scaling Up of Expression and Isolation of Membranes | 396 |
| 14.2.4 | Identification of a Suitable Detergent Using Fluorescence-Detection Size-Exclusion Chromatography | 398 |
| 14.2.5 | Purification of the Membrane Protein GFP-Fusion and Recovery of the Membrane Protein from the Fusion | 399 |
| 14.3 | Materials | 402 |
| 14.3.1 | Reagents | 402 |
| 14.3.2 | Equipment | 403 |
| 14.4 | Expression and Isolation of GFP-His ₈ | 403 |
| 14.5 | Conclusions | 404 |
| | Acknowledgments | 405 |
| | Abbreviations | 405 |
| | References | 405 |

Index 407